Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.

Richardson, Peter; Griffin, Ivan; Tucker, Catherine; Smith, Dan; Oechsle, Olly; Phelan, Anne; Rawling, Michael; Savory, Edward; Stebbing, Justin

Richardson, Peter; Griffin, Ivan; Tucker, Catherine; Smith, Dan; Oechsle, Olly; Phelan, Anne; Rawling, Michael; Savory, Edward; Stebbing, Justin.

Richardson P; BenevolentAI, London, UK.
Griffin I; BenevolentAI, London, UK.
Tucker C; BenevolentAI, London, UK.
Smith D; BenevolentAI, London, UK.
Oechsle O; BenevolentAI, London, UK.
Phelan A; BenevolentAI, London, UK.
Rawling M; BenevolentAI, London, UK.
Savory E; BenevolentAI, London, UK.
Stebbing J; Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK. Electronic address: j.stebbing@imperial.ac.uk.

Lancet ; 395(10223): e30-e31, 2020 02 15.

Article in English | MEDLINE | ID: covidwho-217

Subject(s)

Azetidines/therapeutic use; Betacoronavirus/drug effects; Coronavirus Infections/drug therapy; Pneumonia, Viral/drug therapy; Sulfonamides/therapeutic use; COVID-19; Humans; Pandemics; Purines; Pyrazoles; SARS-CoV-2; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Sulfonamides / Azetidines / Coronavirus Infections / Betacoronavirus Limits: Humans Language: English Journal: Lancet Year: 2020 Document Type: Article Affiliation country: S0140-6736(20)30304-4

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google